BACKGROUND: Low-grade gliomas (LGGs) are uncommon in older patients, and long-term clinical behavior and prognostic factors are not well defined in this group. METHODS: The authors retrospectively searched their tumor registry for the records of adult patients (> or =18 years) diagnosed as having nonpilocytic LGG between 1960 and 1992 at Mayo Clinic. The Kaplan-Meier method was used to estimate progression-free survival and overall survival (OS) in patients aged 55 years and older. RESULTS: Of 314 patients initially identified, 32 were aged at least 55 years, with a median age at diagnosis of 61 years (range, 55-74 years). Median follow-up was 17.3 years for survivors. Operative pathologic diagnoses comprised astrocytoma (n = 22, 69%), mixed oligoastrocytoma (n = 7, 22%), and oligodendroglioma (n = 3, 9%). Gross total resection was achieved in 1 patient, radical subtotal resection in 1, and subtotal resection in 14; 16 patients had biopsy only. Postoperative radiotherapy or chemotherapy was given to 23 (72%) patients and 1 (3%) patient, respectively. Median OS was 2.7 years for all patients: 3 years with resection and 2.2 years with biopsy only (P = .58). The 5- and 10-year OS rates were 31% and 18%, respectively. Factors adversely affecting OS on univariate analysis were enhancement on computed tomography (P < .001) and supratentorial location (P = .03). CONCLUSIONS: This retrospective series of older patients suggests that intracranial LGG in this age group behaves aggressively. Pathologic sampling error failing to recognize higher-grade tumors does not seem to account for these poor outcomes. Aggressive management with maximally safe resection followed by adjuvant therapy should be strongly considered.
BACKGROUND: Low-grade gliomas (LGGs) are uncommon in older patients, and long-term clinical behavior and prognostic factors are not well defined in this group. METHODS: The authors retrospectively searched their tumor registry for the records of adult patients (> or =18 years) diagnosed as having nonpilocytic LGG between 1960 and 1992 at Mayo Clinic. The Kaplan-Meier method was used to estimate progression-free survival and overall survival (OS) in patients aged 55 years and older. RESULTS: Of 314 patients initially identified, 32 were aged at least 55 years, with a median age at diagnosis of 61 years (range, 55-74 years). Median follow-up was 17.3 years for survivors. Operative pathologic diagnoses comprised astrocytoma (n = 22, 69%), mixed oligoastrocytoma (n = 7, 22%), and oligodendroglioma (n = 3, 9%). Gross total resection was achieved in 1 patient, radical subtotal resection in 1, and subtotal resection in 14; 16 patients had biopsy only. Postoperative radiotherapy or chemotherapy was given to 23 (72%) patients and 1 (3%) patient, respectively. Median OS was 2.7 years for all patients: 3 years with resection and 2.2 years with biopsy only (P = .58). The 5- and 10-year OS rates were 31% and 18%, respectively. Factors adversely affecting OS on univariate analysis were enhancement on computed tomography (P < .001) and supratentorial location (P = .03). CONCLUSIONS: This retrospective series of older patients suggests that intracranial LGG in this age group behaves aggressively. Pathologic sampling error failing to recognize higher-grade tumors does not seem to account for these poor outcomes. Aggressive management with maximally safe resection followed by adjuvant therapy should be strongly considered.
Authors: K Lote; T Egeland; B Hager; B Stenwig; K Skullerud; J Berg-Johnsen; I Storm-Mathisen; H Hirschberg Journal: J Clin Oncol Date: 1997-09 Impact factor: 44.544
Authors: Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Martin J van den Bent; Antoine F Carpentier; Alba A Brandes; Marc Sanson; Martin J B Taphoorn; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; Laslo Sipos; Hanny Haaxma-Reiche; Johannes M Kros; Mathilde C M van Kouwenhoven; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: M J van den Bent; D Afra; O de Witte; M Ben Hassel; S Schraub; K Hoang-Xuan; P-O Malmström; L Collette; M Piérart; R Mirimanoff; A B M F Karim Journal: Lancet Date: 2005 Sep 17-23 Impact factor: 79.321
Authors: Elizabeth B Claus; Andres Horlacher; Liangge Hsu; Richard B Schwartz; Donna Dello-Iacono; Florian Talos; Ferenc A Jolesz; Peter M Black Journal: Cancer Date: 2005-03-15 Impact factor: 6.860
Authors: G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan Journal: Neurology Date: 2007-05-22 Impact factor: 9.910
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Priya Kumthekar; Vaibhav Patel; Carly Bridge; Alfred Rademaker; Irene Helenowski; Maciej M Mrugala; Jason K Rockhill; Sean Grimm; Kristin R Swanson; Jeffrey Raizer Journal: Integr Cancer Sci Ther Date: 2017-10-23
Authors: Kunal S Patel; Nelson Moussazadeh; Werner K Doyle; Douglas R Labar; Theodore H Schwartz Journal: J Neurosurg Date: 2013-04-19 Impact factor: 5.115